Top Markets
Coin of the day
LianBio LianBio

LianBio

LIAN
Peringkat dalam Saham #25844
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing... LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus. To further its drug candidates, LianBio has established strategic alliances, including a collaboration with Tarsus Pharmaceuticals, Inc. for the development and commercialization of TP-03, an eye solution for Demodex blepharitis. They also partner with Nanobiotix S.A. for NBTXR3, a radioenhancer designed to be directly administered into malignant tumors before standard radiation therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey.
Harga Saham
$0.42275
Terakhir disinkronkan: 2025-07-14
Kapitalisasi Pasar
$45.81M
Perubahan (1 hari)
-0.89%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan LianBio (LIAN)

Kategori

Pendapatan untuk LianBio (LIAN)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari LianBio, pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan LianBio dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
$12.62B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH
$2.23B -
US